Figure 2 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

Phenotypic characterization of CD70 expression in patients with multiple myeloma. A, Bone marrow aspirates from 30 patients with multiple myeloma were stained with anti-CD70 and anti-BCMA antibodies and assayed by flow cytometry. The percentage of positive cells from the FSC/SSC/Single cells/Live-Dead/CD3−/CD19−/CD20−/CD14−/CD138+ population is plotted, with each dot representing one patient sample. The gating strategy is shown in Supplementary Fig. S3. B, The percentage of positive expression (circle size) and the robust z-score calculated from the mean fluorescence intensity (color) for CD70, BCMA, CD38, CS1, CD56, and CD45 proteins from the same population were plotted in a dot plot for each of the patient samples in (A). C, An optimized stochastic neighbor embedding (opt-SNE) plot was generated for each marker in the CD138+, CD3−, CD19/20−, and CD14− populations from an example patient with amp 1q and loss of one copy of TP53. Representative images of IHC CD70 staining of the gingiva (D) and bone marrow (E) clot of a patient with high-grade myeloma. F, CD70 staining of the humerus of a patient who had not responded to the BCMA antibody–drug conjugate belantamab mafodotin. G, CD70 staining from the bone marrow of a patient without multiple myeloma as a control. Scale bar, 100 μm.